Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines
16 Febbraio 2023 - 1:59PM
Business Wire
Accenture (NYSE: ACN) has made a strategic investment, through
Accenture Ventures, in Ocean Genomics, a technology and AI company
that has developed advanced computational platforms to assist
biopharma companies to discover and develop more effective
diagnostics and therapeutics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230216005238/en/
Accenture has made a strategic
investment, through Accenture Ventures, in Ocean Genomics, a
technology and AI company that has developed advanced computational
platforms to assist biopharma companies to discover and develop
more effective diagnostics and therapeutics. (Graphic: Business
Wire)
Based in Pittsburgh, Ocean Genomics creates software that
provides modeling and an understanding of changes and variants in
mRNA to enable a more accurate prediction of a patient’s biological
response to a drug. The expression of mRNA is a central biological
process that occurs in every cell and helps govern nearly all
aspects of normal functioning and is often disrupted in disease. In
collaboration with Ocean Genomics, biopharma companies use the
technology in in-silico drug discovery to develop treatments based
on an individual's personal biology. The global personalized
medicine market size is expected to reach more than $796 billion by
2028.
Petra Jantzer, Ph.D., a senior managing director and global lead
of Accenture’s Life Sciences practice, said, “The growth of
in-silico in the discovery of individualized treatments and disease
interventions will change how we care for people around the world.
We made this strategic investment in Ocean Genomics to help
biopharma companies better utilize genomic and transcriptomic data
and AI in drug discovery to develop targeted therapeutics at a
higher pace and bring them to market faster.”
Scientific and technological advancements are creating
breakthroughs for patient health, resulting in more complex and
personalized therapies. This New Science, a dynamic combination of
the best in science and health technology, is expected to drive 81
percent of biopharma revenue growth.
“As biopharma companies move to increasingly precise and
effective therapies, they seek the talent, technology and insights
to enable more personalized, data-driven drug discovery,” said Carl
Kingsford, Ph.D., co-founder and CEO of Ocean Genomics. “With the
support of, and collaboration with, Accenture, we will be even
better positioned to help the biopharma industry develop more
effective diagnostics and therapeutics.”
Ocean Genomics is now a part of Accenture Ventures’ Project
Spotlight, an engagement and investment program that connects
emerging technology startups with the Global 2000 to fill strategic
innovation gaps. Project Spotlight offers extensive access to
Accenture’s domain expertise and its enterprise clients, helping
startups harness human creativity and deliver on the promise of
their technology.
“Ocean Genomics’ technology platform integrates gene expression,
molecular features, clinical and genomics data and advanced AI
algorithms to better understand and predict the biological impact
of diseases and therapies,” said Tom Lounibos, managing director,
Accenture Ventures. “With Ocean Genomics now part of Project
Spotlight, we will look to collaborate with our clients in the Life
Sciences industry and beyond on new ways to combine RNA, AI and
other emerging technologies to advance drug development,
personalized medicine, and human health.”
Terms of the transaction were not disclosed.
About Accenture
Accenture is a leading global professional services company that
helps the world’s leading businesses, governments and other
organizations build their digital core, optimize their operations,
accelerate revenue growth and enhance citizen services—creating
tangible value at speed and scale. We are a talent and innovation
led company with 738,000 people serving clients in more than 120
countries. Technology is at the core of change today, and we are
one of the world’s leaders in helping drive that change, with
strong ecosystem relationships. We combine our strength in
technology with unmatched industry experience, functional expertise
and global delivery capability. We are uniquely able to deliver
tangible outcomes because of our broad range of services, solutions
and assets across Strategy & Consulting, Technology,
Operations, Industry X and Accenture Song. These capabilities,
together with our culture of shared success and commitment to
creating 360° value, enable us to help our clients succeed and
build trusted, lasting relationships. We measure our success by the
360° value we create for our clients, each other, our shareholders,
partners and communities. Visit us at www.accenture.com.
About Ocean Genomics
Ocean Genomics is the Intelligent Transcriptome company. We make
the software and provide services that enable our partners to
leverage advanced transcriptomic information and AI to advantage
their discovery and development programs. We partner with
cutting-edge drug developers to supply insights and evidence that
enable data-driven decisions, provide confidence in the underlying
biology, and increase the probability of technical and clinical
success at every step. Our founders are recognized as leading
experts in the fields of computational biology and AI, and
developers of many of the most widely used software methods in gene
expression analysis. Our Intelligent Transcriptome computing
platforms extract extensive gene expression features and analyses
from raw RNA-Seq files (TxomeAI®), and automatically integrate
those features with clinical and other -omics to produce accurate,
actionable models, and discover drug targets and biomarkers
(DiscoverAI™). Our vast database (DeepSea™) provides deeply
characterized transcriptomes, curated metadata, and pre-trained AI
models to add power to discovery and analyses. For more
information, please visit oceangenomics.com and connect with us on
Twitter and LinkedIn.
Copyright © 2023 Accenture. All rights reserved. Accenture and
its logo are trademarks of Accenture.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230216005238/en/
Maggie Nolan Accenture +1 917 452 3964
margaret.d.nolan@accenture.com Christian Harper Accenture +1 917
452 4417 christian.harper@accenture.com
Grafico Azioni Accenture (NYSE:ACN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Accenture (NYSE:ACN)
Storico
Da Apr 2023 a Apr 2024